Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session,
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 and $1.09, further underscoring its momentum heading into the new year.
RBC Capital Sticks to Its Buy Rating for Abbott Laboratories (ABT)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report),
Abbott Laboratories (ABT) Projected to Post Earnings on Wednesday
Abbott Laboratories (NYSE:ABT – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, January 22nd. Analysts expect Abbott Laboratories to post earnings of $1.
Why Abbott Laboratories (ABT) Stock is Currently 2.73% Above from Its 20-Day SMA?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of Abbott Laboratories (ABT)’s shares, while financial institutions hold 76.57%.
Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34. Operator: Good morning and thank you for standing by.
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
MassDevice1d
Abbott sales come up just shy of Q4 expectations on Wall Street, highlights EP growth
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott Laboratories' SWOT analysis: stock poised for growth amid challenges
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...
Abbott Laboratories’ Growth Prospects and Market Leadership in MedTech Justify Buy Rating
BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...